Towards the identification of blood biomarkers for acute stroke in humans: A comprehensive systematic review

British Journal of Clinical Pharmacology

Volumn 74, Issue 2, 2012, Pages 230-240

  Hasan, Nazeeha ^a   McColgan, Peter ^a   Bentley, Paul ^a   Edwards, Robert J ^a   Sharma, Pankaj ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Blood biomarker; Diagnosis; Haemorrhagic stroke; Ischaemic stroke; Meta analysis; Prognosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; HOMOCYSTEINE; PADGEM PROTEIN;

ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; HOSPITAL ADMISSION; HUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STROKE;

BIOLOGICAL MARKERS; HUMANS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84863520098     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04212.x     Document Type: Article

References (77)

1. Department of Health. Reducing brain damage: faster access to better stroke care. National Audit Office Report 2005; 1-60.
2. Office of National Statistics Health Statistics Quarterly. No.47; Autumn 2010.
3. UK Department of Health. National Stroke Strategy. 2007; 1-83.
4. Michel P, Bogousslavsky J. Shared mechanisms of ischaemic and haemorrhagic stroke: still a lot to learn. J Neurol Neurosurg Psychiatry 2006; 77: 1.
5. Kleinig TJ, Vink R. Suppression of inflammation in ischemic and hemorrhagic stroke: therapeutic options. Curr Opin Neurol 2009; 22: 294-301.
6. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53-68.
7. Wang J, Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007; 27: 894-908.
8. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet 2006; 5: 53-63.
9. Cordonnier C, Leys D. Stroke: the bare essentials. Pract Neurol 2008; 8: 263-72.
10. Hand PJ, Kwan J, Lindley RI, Dennis MS, Wardlaw JM. Distinguishing between stroke and mimic at the bedside: the brain attack study. Stroke 2006; 37: 769-75.
11. Wu O, Langhorne P. The challenge of acute-stroke management: does telemedicine offer a solution? Int J Stroke. official journal of the International Stroke Society 2006; 1: 201-7.
12. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006; 63: 661-4.
13. Feuerstein GZ, Chavez J. Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Stroke 2009; 40: (Suppl.): S121-S125.
14. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2: 566-80.
15. Bossuyt PM, Leeflang MM. Chapter 6: developing criteria for including studies. In: Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4[updated September 2008]. The Cochrane Collaboration 2008.
16. Whiteley W, Tseng M-C, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke 2008; 39: 2902-9.
17. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009; 40: e380-9.
18. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-Analyses. Lancet 1999; 354: 1896-900.
19. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13-23.
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
21. Yip H-K, Lai S-L, Lan M-Y, Chang W-N, Liu JS, Kao Y-F, Chang Y-Y, Lu C-H, Chen W-H, Lin H-H, Liou C-W. Time course of platelet activation and von Willebrand factor in patients with non-valvular atrial fibrillation after ischemic stroke. Circ J 2007; 71: 321-6.
22. Waje-Andreassen U, Kråkenes J, Ulvestad E, Thomassen L, Myhr K-M, Aarseth J, Vedeler CA. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005; 111: 360-5.
23. Lu L-F, Yang S-S, Wang C-P, Hung W-C, Yu T-H, Chiu C-A, Chung F-M, Shin S-J, Lee Y-J. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 2009; 18: 354-9.
24. Ben Assayag E, Shenhar-Tsarfaty S, Ofek K, Soreq L, Bova I, Shopin L, Berg RMG, Berliner S, Shapira I, Bornstein NM, Soreq H. Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med 2010; 16: 278-86.
25. de Lau LML, Cheung EYL, Kluft C, Leebeek FWG, Meijer P, Laterveer R, Dippel DWJ, de Maat MPM. Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke. Br J Haematol 2008; 143: 734-7.
26. Weikert C, Westphal S, Berger K, Dierkes J, Möhlig M, Spranger J, Rimm EB, Willich SN, Boeing H, Pischon T. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008; 93: 2647-53.
27. Youssef MYZ, Mojiminiyi OA, Abdella NA. Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease. Transl Res 2007; 150: 158-63.
28. Dvorak F, Haberer I, Sitzer M, Foerch C. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis 2009; 27: 37-41.
29. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957; 2: 200-15.
30. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7.
31. Côté R, Hachinski VC, Shurvell BL, Norris JW, Wolfson C. The Canadian Neurological Scale: a preliminary study in acute stroke. Stroke 1986; 17: 731-7.
32. Côté R, Battista RN, Wolfson C, Boucher J, Adam J, Hachinski V. The Canadian Neurological Scale: validation and reliability assessment. Neurology 1989; 39: 638-43.
33. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61-5.
34. Granger CV, Dewis LS, Peters NC, Sherwood CC, Barrett JE. Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil 1979; 60: 14-7.
35. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20: 864-70.
36. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GDO, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009; 27: 247-53.
37. Liao C-W, Cho W-L, Kao T-C, Su K-E, Lin Y-H, Fan C-K. Blood-brain barrier impairment with enhanced SP, NK-1R, GFAP and claudin-5 expressions in experimental cerebral toxocariasis. Parasite Immunol 2008; 30: 525-34.
38. Foerch C, Curdt I, Yan B, Dvorak F, Hermans M, Berkefeld J, Raabe A, Neumann-Haefelin T, Steinmetz H, Sitzer M. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 2006; 77: 181-4.
39. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38: 376-85.
40. Casas J, Bautista L, Smeeth L, Sharma P, Hingorani A. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005; 365: 224-32.
41. Grotta JC, Welch KM, Fagan SC, Lu M, Frankel MR, Brott T, Levine SR, Lyden PD. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 2001; 32: 661-8.
42. Kidwell CS, Saver JL, Starkman S, Duckwiler G, Jahan R, Vespa P, Villablanca JP, Liebeskind DS, Gobin YP, Vinuela F, Alger JR. Late secondary ischemic injury in patients receiving intraarterial thrombolysis. Ann Neurol 2002; 52: 698-703.
43. Moldes O, Sobrino T, Millán M, Castellanos M, Pérez De La Ossa N, Leira R, Serena J, Vivancos J, Dávalos A, Castillo J. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA. Stroke 2008; 39: 2006-10.
44. Wardlaw JM. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009 Oct 7;(4):CD000213.
45. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32: 2426-32.
46. Saenger AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem 2010; 56: 21-33.
47. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol 2007; 52: 1601-9.
48. Kirschenlohr HL, Griffin JL, Clarke SC, Rhydwen R, Grace AA, Schofield PM, Brindle KM, Metcalfe JC. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 2006; 12: 705-10.
49. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). Exp Oncol 2006; 28: 99-105.
50. Ioannidis JPA, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA. 2011; 305: 2200-10.
51. May A, Wang TJ. Biomarkers for cardiovascular disease: challenges and future directions. Trends Mol Med 2008; 14: 261-7.
52. Hingorani AD, Shah T, Casas JP, Humphries SE, Talmud PJ. C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem 2009; 55: 239-55.
53. Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, Laskowitz DT, Valkirs GE, Buechler KF. Early biomarkers of stroke. Clin Chem 2003; 49: 1733-9.
54. Laskowitz DT, Blessing R, Floyd J, White WD, Lynch JR. Panel of biomarkers predicts stroke. Ann N Y Acad Sci 2005; 1053: 30-30.
55. Tuttolomondo A, Pinto A, Corrao S, Di Raimondo D, Fernandez P, Di Sciacca R, Arnao V, Licata G. Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. Atherosclerosis 2009; 203: 503-8.
56. Cha J-K, Jeong M-H, Kim E-K, Lim Y-J, Ha B-R, Kim S-H, Kim JW. Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke. J Korean Med Sci 2002; 17: 811-6.
57. Nadar SK, Lip GYH, Blann AD. Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project. Thromb Haemost 2004; 92: 1342-8.
58. Dambinova S, Khounteev G, Izykenova G, Zavolokov IG, Ilyukhina AY, Skoromets A. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem 2003; 49: 1752-62.
59. Khan U, Crossley C, Kalra L, Rudd A, Wolfe CDA, Collinson P, Markus HS. Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study. Stroke 2008; 39: 2943-9.
60. Rodríguez-Yáñez M, Castellanos M, Blanco M, García MM, Nombela F, Serena J, Leira R, Lizasoain I, Dávalos A, Castillo J. New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke. Neurology 2006; 67: 1973-8.
61. Sienkiewicz-Jarosz H, Galecka-Wolska M, Bidziński A, Turzyńska D, Sobolewska A, Lipska B, Plaznik ARD. Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol Neurochir Pol 2009; 43: 126-33.
62. Sobrino T, Hurtado O, Moro MA, Rodríguez-Yáñez M, Castellanos M, Brea D, Moldes O, Blanco M, Arenillas JF, Leira R, Dávalos A, Lizasoain I, Castillo J. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 2007; 38: 2759-64.
63. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009; 6: e1000145.
64. Castillo J, Dávalos A, Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 1997; 349: 79-83.
65. Serena J, Leira R, Castillo J, Pumar JM, Castellanos M, Dávalos A. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke 2001; 32: 1154-61.
66. Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-9.
67. Dávalos A, Castillo J, Marrugat J, Fernandez-Real JM, Armengou A, Cacabelos P, Rama R. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology 2000; 54: 1568-74.
68. Gentile NT, Seftchick MW, Huynh T, Kruus LK, Gaughan J. Decreased mortality by normalizing blood glucose after acute ischemic stroke. Acad Emerg Med 2006; 13: 174-80.
69. Shibazaki K, Kimura K, Okada Y, Iguchi Y, Uemura J, Terasawa Y, Kimura K, Okada Y, Iguchi Y, Uemura J, Terasawa Y, Aoki J. Plasma brain natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic stroke. Intern Med 2009; 48: 1601-6.
70. Rallidis LS, Vikelis M, Panagiotakos DB, Liakos GK, Krania E, Kremastinos DT. Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle-aged ischaemic stroke patients. Acta Neurol Scand 2008; 117: 415-20.
71. Undén J, Strandberg K, Malm J, Campbell E, Rosengren L, Stenflo J, Norrving B, Romner B, Lindgren A, Andsberg G. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J Neurol 2009; 256: 72-7.
72. Cocho D, Borrell M, Martí-Fàbregas J, Montaner J, Castellanos M, Bravo Y, Montaner J Molina-Porcel L, Belvís R, Díaz-Manera J-A, Martínez-Domeño A, Martínez-Lage M, Millán M, Fontcuberta J, Martí-Vilalta J-L. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke 2006; 37: 996-9.
73. Alvarez-Sabín J, Molina CA, Ribó M, Arenillas JF, Montaner J, Huertas R, Santamarina E, Rubiera M. Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. Stroke 2004; 35: 2493-8.
74. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck B, Ali L, Restrepo L, Vinuela F, Duckwiler G, Jahan R, Razinia T, Ovbiagele B. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007; 68: 737-42.
75. Katzan IL. Use of tissue-type plasminogen activator for acute ischemic stroke: the cleveland area experience. JAMA 2000; 283: 1151-8.
76. Tanne D. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PA acute stroke survey. Circulation 2002; 105: 1679-85.
77. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, Luijckx GJ, De Keyser J. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J Neurol 2008; 255: 875-80.